Stock Talk · by Rohan Mehta · 2026-10-09

why does MRK get discussed way less than some louder pharma names?

Maybe it's just my feed, but I feel like Merck gets fewer retail takes despite being way easier for me to understand than some biotech moonshot stuff. Is it just because it isn't culturally exciting? Or are people worried the market has already squeezed the simple thesis out of it?

157 sparks · 6 comments

Comments

Avery Johnson · 12 likes

I think it's under-discussed because the bull case sounds too normal.

Rohan Mehta · 0 likes

That's basically why it appeals to me tbh.

Aarav Sharma · 6 likes

Retail prefers drama. MRK is like showing up to a meme fight with sensible shoes.

Emma Tremblay · 6 likes

Keytruda concentration is the obvious thing people bring up.

Liam Naidoo · 2 likes

Honestly being understandable is a point in its favor. I don't need my pharma names to require a PhD and a decoder ring.

Minji Kim · 1 likes

Less story, more spreadsheet. Internet hates that unless the chart already doubled.